Overexpressed nuclear BAG-1 in human hepatocellular carcinoma is associated with poor prognosis and resistance to doxorubicin

Journal of Cellular Biochemistry

Volumn 114, Issue 9, 2013, Pages 2120-2130

  Ni, Wenkai ^a   Chen, Buyou ^a   Zhou, Guoxiong ^a   Lu, Cuihua ^a   Xiao, Mingbing ^a   Guan, Chengqi ^a   Zhang, Yixing ^a   He, Song ^a   Shen, Aiguo ^b   Ni, Runzhou ^a  

^a NANTONG UNIVERSITY   (China)

^b NANTONG MEDICAL COLLEGE   (China)

Author keywords

BCL 2 ASSOCIATED ATHANOGENE 1 (BAG 1); CHEMORESISTANCE; HEPATOCELLULAR CARCINOMA (HCC); NUCLEAR FACTOR B (NF B); PROGNOSIS

Indexed keywords

BAG 1 PROTEIN; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84881384198     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24560     Document Type: Article

References (41)

1. Arlt A, Schafer H,. 2002. NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 40: 336-347.
2. Brimmell M, Burns JS, Munson P, McDonald L, O'Hare MJ, Lakhani SR, Packham G,. 1999. High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers. Br J Cancer 81: 1042-1051.
3. Chen J, Xiong J, Liu H, Chernenko G, Tang SC,. 2002. Distinct BAG-1 isoforms have different anti-apoptotic functions in BAG-1-transfected C33A human cervical carcinoma cell line. Oncogene 21: 7050-7059.
4. Chen HW, Huang XD, Li HC, He S, Ni RZ, Chen CH, Peng C, Wu G, Wang GH, Wang YY, Zhao YH, Zhang YX, Shen AG, Wang HM,. 2012. Expression of FOXJ1 in hepatocellular carcinoma: Correlation with patients' prognosis and tumor cell proliferation. Mol Carcinog DOI: 10.1002/mc.21904
5. Clemo NK, Collard TJ, Southern SL, Edwards KD, Moorghen M, Packham G, Hague A, Paraskeva C, Williams AC,. 2008. BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity. Carcinogenesis 29: 849-857.
6. Cutress RI, Townsend PA, Bateman AC, Johnson PW, Ryder K, Barnes DM, Packham G,. 2001. BAG-1 immunostaining and survival in early breast cancer. J Clin Oncol 19: 3706-3707.
7. Das KC, White CW,. 1997. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 272: 14914-14920.
8. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC,. 1998. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17: 2215-2223.
9. Ding Z, Yang X, Pater A, Tang SC,. 2000. Resistance to apoptosis is correlated with the reduced caspase-3 activation and enhanced expression of antiapoptotic proteins in human cervical multidrug-resistant cells. Biochem Biophys Res Commun 270: 415-420.
10. Dolcet X, Llobet D, Pallares J, Matias-Guiu X,. 2005. NF-kB in development and progression of human cancer. Virchows Arch 446: 475-482.
11. Elliott E, Ginzburg I,. 2009. BAG-1 is preferentially expressed in neuronal precursor cells of the adult mouse brain and regulates their proliferation in vitro. FEBS Lett 583: 229-234.
12. Fei M, Lu M, Wang Y, Zhao Y, He S, Gao S, Ke Q, Liu Y, Li P, Cui X, Shen A, Cheng C,. 2009. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med Oncol 26: 178-185.
13. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS, Jr., 1999. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19: 5785-5799.
14. Hinitt CA, Wood J, Lee SS, Williams AC, Howarth JL, Glover CP, Uney JB, Hague A,. 2010. BAG-1 enhances cell-cell adhesion, reduces proliferation and induces chaperone-independent suppression of hepatocyte growth factor-induced epidermal keratinocyte migration. Exp Cell Res 316: 2042-2060.
15. Karin M, Lin A,. 2002. NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227.
16. Kikuchi R, Noguchi T, Takeno S, Funada Y, Moriyama H, Uchida Y,. 2002. Nuclear BAG-1 expression reflects malignant potential in colorectal carcinomas. Br J Cancer 87: 1136-1139.
17. Kreuz S, Siegmund D, Scheurich P, Wajant H,. 2001. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 21: 3964-3973.
18. Liu HY, Wang ZM, Bai Y, Wang M, Li Y, Wei S, Zhou QH, Chen J,. 2009. Different BAG-1 isoforms have distinct functions in modulating chemotherapeutic-induced apoptosis in breast cancer cells. Acta Pharmacol Sin 30: 235-241.
19. Llovet JM, Bruix J,. 2003. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442.
20. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J,. 2002. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359: 1734-1739.
21. Lu M, Ma J, Xue W, Cheng C, Wang Y, Zhao Y, Ke Q, Liu H, Liu Y, Li P, Cui X, He S, Shen A,. 2009. The expression and prognosis of FOXO3a and Skp2 in human hepatocellular carcinoma. Pathol Oncol Res 15: 679-687.
22. Maier JV, Volz Y, Berger C, Schneider S, Cato AC,. 2010. Depletion of the cellular levels of Bag-1 proteins attenuates phorbol ester-induced downregulation of IkappaBalpha and nuclear accumulation of NF-kappaB. Biochem Biophys Res Commun 401: 406-411.
23. Millar EK, Anderson LR, McNeil CM, O'Toole SA, Pinese M, Crea P, Morey AL, Biankin AV, Henshall SM, Musgrove EA, Sutherland RL, Butt AJ,. 2009. BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. Br J Cancer 100: 123-133.
24. Munoz A, Chen JG, Egner PA, Marshall ML, Johnson JL, Schneider MF, Lu JH, Zhu YR, Wang JB, Chen TY, Kensler TW, Groopman JD,. 2011. Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China. Carcinogenesis 32: 860-865.
25. Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL,. 2011. The NFkappaB pathway: A therapeutic target in glioblastoma. Oncotarget 2: 646-653.
26. Patt YZ, Hoque A, Roh M, Ellis L, Lozano R, Carrasco CH, Charnsangavej C, Cleary K,. 1999. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: A communication. Am J Clin Oncol 22: 209-213.
27. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y,. 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466.
28. Sourisseau T, Desbois C, Debure L, Bowtell DD, Cato AC, Schneikert J, Moyse E, Michel D,. 2001. Alteration of the stability of Bag-1 protein in the control of olfactory neuronal apoptosis. J Cell Sci 114: 1409-1416.
29. Southern SL, Collard TJ, Urban BC, Skeen VR, Smartt HJ, Hague A, Oakley F, Townsend PA, Perkins ND, Paraskeva C, Williams AC,. 2012. BAG-1 interacts with the p50-p50 homodimeric NF-kappaB complex: Implications for colorectal carcinogenesis. Oncogene 31: 2761-2772.
30. Staudt LM,. 2010. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2: a000109.
31. Takahashi M, Saito H, Atsukawa K, Ebinuma H, Okuyama T, Ishii H,. 2003. Bcl-2 prevents doxorubicin-induced apoptosis of human liver cancer cells. Hepatol Res 25: 192-201.
32. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC,. 1995. Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity. Cell 80: 279-284.
33. Townsend PA, Cutress RI, Sharp A, Brimmell M, Packham G,. 2003. BAG-1: A multifunctional regulator of cell growth and survival. Biochim Biophys Acta 1603: 83-98.
34. Townsend PA, Stephanou A, Packham G, Latchman DS,. 2005. BAG-1: A multi-functional pro-survival molecule. Int J Biochem Cell Biol 37: 251-259.
35. Turner BC, Krajewski S, Krajewska M, Takayama S, Gumbs AA, Carter D, Rebbeck TR, Haffty BG, Reed JC,. 2001. BAG-1: A novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol 19: 992-1000.
36. Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS,. 2001. NF-kappa B-mediated chemoresistance in breast cancer cells. Surgery 130: 143-150.
37. Witcher M, Yang X, Pater A, Tang SC,. 2001. BAG-1 p50 isoform interacts with the vitamin D receptor and its cellular overexpression inhibits the vitamin D pathway. Exp Cell Res 265: 167-173.
38. Xiao MB, Jiang F, Ni WK, Chen BY, Lu CH, Li XY, Ni RZ,. 2012. High expression of S100A11 in pancreatic adenocarcinoma is an unfavorable prognostic marker. Med Oncol 29: 1886-1891.
39. Yang X, Hao Y, Ferenczy A, Tang SC, Pater A,. 1999. Overexpression of anti-apoptotic gene BAG-1 in human cervical cancer. Exp Cell Res 247: 200-207.
40. Yoo BK, Chen D, Su ZZ, Gredler R, Yoo J, Shah K, Fisher PB, Sarkar D,. 2010. Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Res 70: 3249-3258.
41. Zapata JM, Krajewska M, Krajewski S, Huang RP, Takayama S, Wang HG, Adamson E, Reed JC,. 1998. Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat 47: 129-140.